aod9604 mechanism of action lipolysis Mechanisms Disease: metabolic effects of growth hormone and insulin-like growth factor 1 AOD-9604 vs. Tesamorelin vs. Semaglutide:

This applies to all conditions listed with diabetes in the Index (CKD, neuropathy, retinopathy, etc.)

Classified as a selective Nicotinamide N-methyltransferase (NNMT) small-molecule inhibitor, this quaternary ammonium compound achieves around 38.4% oral bioavailability in rodent trials, an acceptable absorption rate for positively charged quinolinium derivatives that typically face poor intestinal permeability

[1] It is prepared in a 30 mL multi-dose vial with a preservative (2 % benzyl alcohol) for multiple withdrawals

This compound is not approved by the FDA for any use and is supplied strictly for in-vitro laboratory research use only